Swiss Biotech Day to shed light on 13 emerging startups

The Swiss Biotech Day (SBD) attracts every year more than 650 participants comprising of entrepreneurs, investors, researchers, analysts, BD&L, political decision-makers, industry stakeholders and media. The upcominig SBD on 7th May offers various opportunities to learn and discover new trends in the industry through keynotes - this year by Jean-Paul Clozel, Idorsia, and Patrick Aebischer, former EPFL presidentand - thematically focused panel discussions on topics such as finance, production and licensing. Attendees will also have the opportunity to engage and discuss with like-minded people in pre-scheduled one-to-one partnering meetings and during the exhibitions.

For established and emerging startups in the Biotech sector, the SBC is an ideal platform to present their success stories and innovations respectively. The organizing committee has selected nine established startups and thirteen emerging startups to present before the audience.

The Emerging Biotech Companies include:

Abologix (GE) – the startup in stealth mode with very experienced board members specializes in the development of pharmaceutical products.

AC BioScience (VD) –is developing new therapies to fight a wide range of cancers.

Anaveon (ZH) – the University of Zurich Spinoff is developing immunotherapies for cancer.

ARTIDIS (BS) – the spin-off from the University of Basel with its ARTIDIS nanotechnology platform aims to facilitate personalized therapy through automatic, fast and reliable tissue diagnostics.

Gain Therapeutics (TI) - developed an advanced computational technology for identifying next-generation brain-penetrant non-competitive pharmacological chaperones for rare treating diseases.

InterAx Biotech (AG) – the startup is a pioneer in computational pharmacology for drug discovery. Its technology can accurately determine the reaction of receptors to which 40% of all drugs bind.

Nemis Technologies (ZH) – is developing diagnostic kits for faster, highly specific and safe microbiological detection in food safety, hospital and clinical applications and water treatment.

Novaremed (BS) – is developing a compound (NRD.E1) for the treatment of Diabetic Neuropathic Pain

PreComb Therapeutics (ZH) – is developing a phenotypical drug development platform using 3D microtissue culture to enable high-throughput combinatorial drug screening

Tepthera (BS) – founded as a spin-off from the Institute of Molecular Health Sciences at the ETH Zurich, the startup offers individualized therapeutic cancer vaccines.

TOLREMO therapeutics (ZH) – the ETH Spin-off is developing a new therapeutic approach that eradicates cancer cells that cause drug resistance.

Versameb (BS) – focusing on regenerative medicine, the startup developed a proprietary technology platform for optimized and tailored, local delivery of therapeutic proteins.

Versantis (ZH) – the ETH Zurich spinoff specializes in the diagnosis, prevention and treatment of liver diseases.

The established biotech startups that will present parallel to the emerging startups include Santhera, Newron, Addex, InnoMedica, Jennewein, Helsinn Healthcare, GeNeuro, NBE Therapeutics and IQVIA.

The detailed program is available on the SBD website and registration is still open.

(RAN)